Company Description
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States.
It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.
Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatment of atopic dermatitis and other dermatologic conditions; Bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2a trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; Zunsemetinib (ATI-450), a mitogen-activated protein kinase-activated protein kinase 2 inhibitor under Phase 1b/2 trials for the treatment of metastatic breast cancer and pancreatic ductal adenocarcinoma; and ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in preclinical stage to treat various atopic, immunologic, and respiratory diseases, as well as an ITK selective inhibitor candidate for the treatment of autoimmune diseases.
Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
| Country | United States |
| Founded | 2012 |
| IPO Date | Oct 7, 2015 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 64 |
| CEO | Neal Walker |
Contact Details
Address: 701 Lee Road, Suite 103 Wayne, Pennsylvania 19087 United States | |
| Phone | 484 324 7933 |
| Website | aclaristx.com |
Stock Details
| Ticker Symbol | ACRS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001557746 |
| CUSIP Number | 00461U105 |
| ISIN Number | US00461U1051 |
| Employer ID | 46-0571712 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Neal S. Walker D.O., M.D. | Co-Founder, Chief Executive Officer and Chairman |
| Dr. Hugh M. Davis Ph.D. | President, Chief Operating Officer and Director |
| Kevin Balthaser | Chief Financial Officer |
| Dr. Joseph Monahan Ph.D. | Chief Scientific Officer |
| Matthew Rothman J.D. | General Counsel and Corporate Secretary |
| Dr. Jon Jacobsen Ph.D. | Senior Vice President of Chemistry |
| James Loerop | Chief Business Officer |
| Steve Tucker | Senior Vice President of Project Leadership |
| Ajay Aggarwal M.B.A., M.D. | Senior Vice President of Clinical Development |
| Dr. Steven Knapp M.S. Pharm.D. | Executive Vice President, Regulatory Affairs and Quality Assurance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 14, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 7, 2025 | EFFECT | Notice of Effectiveness |
| Mar 4, 2025 | UPLOAD | Filing |
| Feb 27, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |
| Feb 12, 2025 | SCHEDULE 13G | Filing |
| Jan 13, 2025 | 8-K | Current Report |
| Dec 31, 2024 | EFFECT | Notice of Effectiveness |